Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases

Eur J Cancer. 2020 Feb:126:91-92. doi: 10.1016/j.ejca.2019.12.009. Epub 2020 Jan 7.

Authors

Yuriko Sugihara¹, Taketo Kawai², Daisuke Yamada³, Chiaki Furuyama³, Yusuke Sato¹, Haruki Kume¹

Affiliations

¹ Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
² Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address: [email protected].
³ Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

PMID: 31923731
DOI: 10.1016/j.ejca.2019.12.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Transitional Cell / drug therapy*
Carcinoma, Transitional Cell / pathology
Female
Foot Dermatoses / chemically induced
Foot Dermatoses / diagnosis*
Humans
Male
Neoplasm Metastasis
Onychomycosis / chemically induced
Onychomycosis / diagnosis*
Urologic Neoplasms / drug therapy*
Urologic Neoplasms / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab